cyno see hit ep guid low end
close today file provid updat impact
voluntari recal vitalia link compani expect hit
cynosur cyno due lost sale refund previou sale vitalia
handpiec unus probe tempsur system lower sale monalisa
touch mlt hit revenu vitalia
compani previous expect bigger headwind anticip management
expect cyno impact off-set strong top-lin growth part
core busi re-affirmed prior revenu guid
although management see ep lower end rang
lack visibl make difficult recommend share
point fiscal financi impact cyno recal fda concern
surround vr market hard quantifi unclear may
reintroduc vitalia extent mlt sale reduc see vr vagin
rejuven takeaway women health expert dinner said
on-going lack visibl concern continu headwind cyno well
uncertainti surround upcom contract renew make hard
us remain buy despit discount peer even though core busi
appear solid downgrad share neutral buy
lower est cut po downgrad share neutral
lower revenu rais core sale
forecast off-set cyno lower revenu
remov vitalia new forecast assum organ revenu growth
adjust blood screen also lower ep estimate
due combin lower sale higher share count recent
convers management suggest priorit tuck-in deal
share buyback higher interest expens new po remain
base calendar ep estimate in-lin three-yr
net dbt
cyno headach limit
visibl downgrad neutral po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi diagnost
busi deliv solid perform
especi ou market help
partial off-set issu relat
cynosur busi acquir continu
reserv cynosur
lack visibl concern although
po base approxim calendar ep estim impli
ev/ebitda in-line three-year histor averag
discount compani dx/medtech peer multipl
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
downsid risk po
cynosur competit pressur slower uptak reimburs new product
unfavor chang clinic practic guidelin manag departur regulatori
risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
